Summary
Acetylator phenotype has been determined with sulphamethazine (sulphadimidine) in 69 Spanish patients with rheumatoid arthritis (48 females), all of whom were on second line therapy, and in 96 age-matched normal controls (54 females).
Thirty-two patients (46.4%) and 56 controls (58.3%) were classified as slow acetylators. On analysing separately the females in both groups, 37.5% of patients and 63% of controls were found to be slow acetylators.
No difference was found in the males (patients 66.3% and controls 52.4% slow acetylators).
Rapid acetylator phenotype may be a risk factor for the development of severe rheumatoid arthritis in women.
This is a preview of subscription content, log in via an institution to check access.
References
Price-Evans DA, Manley KA, McKusick VA (1964) Genetic control of isoniazid metabolism in man. Lancet II: 485–491
Price-Evans DA (1989) N-Acetyltransferase. Pharmacol Ther 42: 157–234
Masi AT, Medsger TA (1989) Epidemiology of the rheumatic diseases. In: McCarthy DJ (ed) Arthritis and allied conditions. Lea & Febiger, Philadelphia, pp 16–54
Arnett FC, Edworthy SM, Bloch DA, McShane J, Fries JS, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustedt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid artritis. Arthritis Rheum 31: 315–324
Price-Evans DA (1969) An improved and simplified method of detecting the acetylator phenotype. J Med Genet 6: 405–407
Viznerovà A, Slavikovà Z, Ellard G (1973) The determination of acetylator phenotype in tuberculosis patients in Czechoslovakia using sulfadimidine. Tubercle 54: 67–71
Mitchell D (1985) Epidemiology. In: Utsinger PD, Zuaifler NJ, Ehrlich GE (eds) Lippincott, Philadelphia, pp 133–150
Utsinger PD, Katz WA (1988) Rheumatoid arthritis — diagnosis. In: Katz WA (ed) Diagnosis and management of rheumatic diseases. Lippincott, Philadelphia, pp 345–379
Ehrenfeld M, Zylber-Katz E, Levy M (1983) Acetylator phenotype in rheumatoid arthritis. Isr J Med Sci 19: 368–370
Dalqvist SR, Mjörndal T (1987) Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or D-penicillamine. Scand J Rheumatol 16: 235–239
Amos RS, Bax DE, Greaves MS (1986) Sulphasalazine therapy in RA. Ann Rheum Dis 45: 439
Chalmers IM, Sitar DS, Hunter T (1990) A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 17: 764–770
Taggart AJ, Hill J, Astbury C, Dixon JS, Bird HA, Wright V (1987) Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol 26: 32–36
Crook PR, Hortas C, Roberts EJM, Swinson DR, Mucklow JC, Shadforth MF (1983) Acetylator phenotype and the effect of dapsone in rheumatoid arthritis. J Rheumatol 10: 805–808
Leden I, Hanson A, Melander A, Sturfelt G, Svensson B, W»hlin-Boll (1981) Varying distribution of acetylation phenotypes in RA patients with and without Sjögren syndrome. Scand J Rheumatol 10: 253–255
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ladero, J.M., Andres, M.P., Bañares, A. et al. Acetylator polymorphism in rheumatoid arthritis. Eur J Clin Pharmacol 45, 279–281 (1993). https://doi.org/10.1007/BF00315397
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315397